Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: VLAD who wrote (6111)	3/24/1998 7:17:00 AM
From: ChinuSFO	Respond to of 23519

<<Vivus management would be smart enough to know that they are "in the fish bowel">> Freudian slip? Exceedingly accurate. Best Regards, CR

To: VLAD who wrote (6111)	3/24/1998 1:42:00 PM
From: LoLoLoLita	Read Replies (1) \| Respond to of 23519

Ysterday's good news (with some scepticism) on PFE/Viagra FYI: -------------------------------------------------------------- Monday March 23, 11:55 am Eastern Time Pfizer jumps after television report on Viagra NEW YORK, March 23 (Reuters) - Shares of Pfizer Inc (PFE - news) jumped Monday after the spotlight on its candidate impotence drug Viagra grew even brighter with a positive feature Friday on the ABC News television program ''20/20.'' Pfizer shares were up 3-13/16 to 95-15/16 in morning trade, continuing last week's sharp rise on expectations the U.S. Food and Drug Administration this month will approve the oral tablet treatment for male erectile dysfunction. ''The '20/20' report could not have been more positive even if Pfizer had written the script itself,'' said Hambrecht & Quist analyst Alex Zisson. ''They interviewed a guy who used Viagra and spoke to his wife and they both said it worked very well and had no side effects. And they said it had changed their lives,'' Zisson said, adding that all clinicians and patients interviewed spoke favorably of the drug. The FDA, which is reviewing Viagra on an expedited six-month timetable, is expected to decide by March 29 whether to grant marketing approval. Some analysts have predicted Viagra, if approved, will generate revenues of $2 billion by the year 2001 and sales of $5 billion or more in subsequent years. However, others say market hopes for the drug are overly exuberant and that a sales disappointment could pressure Pfizer stock, now trading at about 47 times projected 1998 earnings, compared with a P/E ratio of 33 for the drug group. Pfizer shares have jumped 12 percent since March 13, helped by snowballing media attention on Viagra (sildenafil) as it heads closer to drugstore shelves. Pfizer is also awaiting FDA approval this month for Zeldox (ziprasidone), a schizophrenia drug that would compete with Eli Lilly and Co.'s (LLY - news) blockbuster Zyprexa (olanzapine) and with Zeneca Group Plc's (quote from Yahoo! UK & Ireland: ZEN.L) Seroquel (quetiapine). --------------------------------------------------------------------------------